OMERS ADMINISTRATION Corp Makes New Investment in Kenvue Inc. $KVUE

OMERS ADMINISTRATION Corp purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, Holdings Channel reports. The fund purchased 305,233 shares of the company’s stock, valued at approximately $5,833,000.

A number of other large investors have also recently modified their holdings of the company. Physician Wealth Advisors Inc. grew its stake in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares in the last quarter. Elyxium Wealth LLC purchased a new position in Kenvue during the 4th quarter worth $26,000. Johnson Financial Group Inc. bought a new stake in Kenvue during the 2nd quarter valued at $26,000. MV Capital Management Inc. bought a new stake in Kenvue during the 4th quarter valued at $28,000. Finally, CoreCap Advisors LLC lifted its holdings in shares of Kenvue by 64.9% in the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after buying an additional 591 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on KVUE. UBS Group dropped their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Finally, Barclays increased their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average target price of $19.27.

Kenvue Stock Up 1.8%

Kenvue stock opened at $19.41 on Tuesday. The business has a fifty day moving average of $19.08 and a two-hundred day moving average of $18.21. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The firm has a market cap of $37.27 billion, a P/E ratio of 22.30, a P/E/G ratio of 1.36 and a beta of 0.47. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $21.63.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. During the same period last year, the business posted $0.29 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. On average, analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be given a dividend of $0.21 per share. The ex-dividend date of this dividend is Wednesday, August 12th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 dividend on an annualized basis and a yield of 4.3%. Kenvue’s dividend payout ratio is 96.55%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.